Jefferies Group Lowers Ampio Pharmaceuticals to Hold (AMPE)
Ampio Pharmaceuticals (NASDAQ:AMPE) was downgraded by research analysts at Jefferies Group from a “buy” rating to a “hold” rating in a report released on Friday, TheFlyOnTheWall.com reports.
Shares of Ampio Pharmaceuticals (NASDAQ:AMPE) opened at 5.66 on Friday. Ampio Pharmaceuticals has a one year low of $5.07 and a one year high of $10.86. The stock’s 50-day moving average is $6.75 and its 200-day moving average is $7.01. The company’s market cap is $294.2 million.
Ampio Pharmaceuticals (NASDAQ:AMPE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.07. On average, analysts predict that Ampio Pharmaceuticals will post $-1.05 earnings per share for the current fiscal year.
A number of other firms have also recently commented on AMPE. Analysts at Aegis reiterated a “buy” rating on shares of Ampio Pharmaceuticals in a research note on Thursday.
Ampio Pharmaceuticals, Inc (NASDAQ:AMPE) is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.